

SARDA PROTEINS LIMITED

Reg Off:G-1-177 (A), Matsya Industrial Area, Alwar-301030 (Rajasthan),
Phone: 0144-2881392, E Mail: sardaproteins@yahoo.com, website: www.sardaproteins.com
CIN: L15142RJ1991PLC006353

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON 31st December 2016 Part - I

Rs.in Lakhs							
Sl.	Particulars	3 Months Ended 31.12.16 (Unaudited)	Preceding 3 months ended 30.09.16 (Unaudited)	Corresponding 3 months ended in previous year 31.12.15 (Unaudited)	Year to date figures for current period ended 31.12.16 (Unaudited)	Year to date figures for previous period ended 31.12.15 (Unaudited)	Year Ended 31.03.16 (Audited)
1	Net Sales/Income from Operations	159.52	144.17	63.59	393.21	178.17	195.42
	Other Operative Income	1.36	1.52	2.09	4.76	7.22	10.77
2	Total Income from Operations (Net)	160.88	145.69	65.68	397.97	185.39	206.19
	Total Expenditure						
	a) Cons. of Material	0.00	0.00	0.00	0.00	0.00	0.00
	b) Purchase of Stock in Trade	136.85	145.24	142.93	352.92	288.59	294.55
	c) (Increase)/decrease in stock in trade	23.59	(12.85)	(74.53)	27.49	(117.23)	(115.52)
	d) Employee Benefit Expenses	5.54	4.58	4.81	14.65	14.34	19.05
	e) Depreciation and Amortisation Expenses	0.33	0.33	0.40	1.06	1.38	1.77
	f) Other expenditure	3.76	7.96	4.39	17.58	16.88	20.51
3	Total Expenses	170.07	145.26	78.00	413.70	203.96	220.36
	Profit/(Loss) from operations before other Income, finance cost and exceptional items (1-2)						
	Other Income	(9.19)	0.43	(12.32)	(15.73)	(18.57)	(14.17)
5	Profit/(Loss) from ordinary activities before finance cost and exceptional items (3+-4)	(0.10)	0.10	(0.09)		0.00	0.17
6	Finance Cost	(9.29)	0.53	(12.41)	(15.73)	(18.57)	(14.00)
7	Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5+-6)	0.08	0.41	0.15	1.21	0.98	2.78
8	Exceptional Items	(9.37)	0.12	(12.56)	(16.94)	(19.55)	(16.78)
9	Profit/(Loss) from ordinary activities before tax (7+- 8)	0.00	0.00	0.00	0.00	0.00	0.00
10	Tax Expenses/ Deferred Tax (Asset)/ Liability	(9.37)	0.12	(12.56)	(16.94)	(19.55)	(16.78)
11	Net Profit/(Loss)(-) from ordinary activities after tax (9+-10)	0.00	0.00	0.00	0.00	(1.16)	(1.41)
12	Extraordinary items (net of tax Rs. Expenses Lakhs)	(9.37)	0.12	(12.56)	(16.94)	(18.39)	(15.37)
13	Net Profit/(Loss)(-) for the period (11+-12)	0.00	0.00	0.00	0.00	0.00	0.00
14	Share of Profit/(loss) of associates *	(9.37)	0.12	(12.56)	(16.94)	(18.39)	(15.37)
15	Minority Interest *	0.00	0.00	0.00	0.00	0.00	0.00
16	Net/Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates (13+-14+-15)	0.00	0.00	0.00	0.00	0.00	0.00
17	Paid up Equity Share Capital Face Value Rs. 10.00 each	(9.37)	0.12	(12.56)	(16.94)	(18.39)	(15.37)
18	Reserves excluding Revaluation reserves as per Balance Sheet of previous accounting year	172.59	172.59	172.59	172.59	172.59	172.59
19	Earning per share before extraordinary items) in Rs. (not annualised)						14.83
	Basic	(0.54)	0.01	(0.73)	(0.98)	(1.07)	(0.89)
	Diluted	(0.54)	0.01	(0.73)	(0.98)	(1.07)	(0.89)


- Notes:
- The above results have been reviewed by the Audit Committee and approved by Board of Directors at the meeting held on 28th January 2016
 - Segment reporting as defined in Accounting Standard 17 is not applicable as company having only one segment.
 - Other Expenses include loss from the hedging of M.Seed in commodity exchange for Rs. 3.20 Lakhs.
 - There were no investor complaints pending as on January 1, 2017 nor received during the quarter ended 31.12.2016.

Place: Alwar
Date : 28-Jan-2017



on behalf of the Board

D.P. Sarda
D.P. SARDA (DIN:00763377)
Directors



Amit Agarwal

Chartered Accountant

Review Report to Sarda Proteins Limited, Alwar

We have reviewed the accompanying statement of unaudited financial results of Sarda proteins limited, G-1-177 (A), MIA , ALWAR-301030 for the period ended 31ST December, 2016 . This statement is the responsibility of the company's management and has been approved by the board of directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2400, *engagements to review financial statements* issued by the institute of chartered accountants of India. This standard requires that we plan and perform the review to obtain the moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquires of company personal and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable accounting standard and other recognized accounting practices and policies has not disclosed the information required to be disclose in terms of regulation 33 of the SEBI (listing obligations and disclosures requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR AMIT M AGARWAL & CO
Chartered Accountants
FRN NO. 019025C



AMIT AGARWAL
(Proprietor)
M. No. 527293

Place: Alwar

Dated: 28/01/2017